ALTERITY THERAPEUTICS (ATHE) FIRESIDE CHAT - ALLARITY THERAPEUTICS INC

Explicit Guidance:

• Clinical Milestones: First patient dosing (FPD) expected in the first quarter of next year.
• Financial Runway: Current cash balance of $25–30 million is sufficient to fund operations through the start of the Phase 3 trial, covering regulatory and setup activities.
• Study Design Targets: Primary endpoint analysis aims to power for a treatment effect of 2.0 to 2.5 points on the MSA Rating Scale (MSAR), though a 1.5-point improvement is deemed the minimum clinically important difference.
• Dose Strategy: 50 mg BID selected as the pivotal dose based on saturation of effect and flat dose-response curve; 75 mg BID excluded from pivotal selection despite lower toxicity profile.

Business-Segment Outlook:

• Product (ATH434): Proceeding with a multinational Phase 3 pivotal study targeting patients with Multi-System Atrophy (MSA).
• Patient Population: Utilizing refined selection criteria leveraging MRI signatures (brain atrophy in specific regions, elevated brain iron) and plasma/neurofilament light chain (NFL) biomarkers to distinguish MSA from Parkinson's and other parkinsonian disorders, reducing enrollment speed but increasing signal clarity.
• Endpoints: Primary endpoint is the 11-item MSAR; secondary endpoints include patient-reported outcomes (PROs) and objective measures of physical activity to capture benefits in immobility, speech, and swallowing.
• Analysis Methodology: Adoption of a mixed model with repeated measures to harmonize clinical and neuroimaging data for the Phase 3 analysis.

Market and Competitive Outlook:

• Competitive Positioning: Emphasis on the lack of approved therapies for MSA and the urgent need for disease-modifying treatments in a "fragile patient population."
• Enrollment Dynamics: Acknowledges that rapid recruitment without rigorous biomarker screening increases the risk of a "negative trial" due to patient heterogeneity; prioritizes slow, high-quality enrollment to ensure diagnostic certainty.
• Market Expectation: A treatment effect of 1.5 to 2 points on the MSAR (e.g., transitioning from "slow movement" to "no impairment" or "occasional choking" to "no choking") is viewed as highly meaningful for label acquisition and patient impact.

Macro / Industry Outlook:

• Regulatory Alignment: Achieved alignment with the FDA on critical aspects including primary/secondary endpoints, patient selection strategies (including use of spinal fluid NFL and blood pressure covariates), and the overall safety database size.
• Geographic Expansion: Trial design includes a multinational footprint with planned sites in the U.S., several European countries, and Australia.
• Investment Landscape: Management is actively evaluating partnership opportunities versus capital raises; while open to dilution, the priority is securing a "thoughtful development partner" capable of delivering results rather than merely minimizing near-term dilution.

Strategic Initiatives:

• Publication: Commitment to publishing Phase 2 results in the near term (current delay attributed to team size).
• Trial Activation: Goal to activate sites in the U.S., Europe, and Australia once regulatory approvals are secured in those jurisdictions.
• Data Refinement: Integration of "natural history" (Biomuse) data to refine MRI-based patient identification (shifting focus from iron to brain volume for operational ease).

Risks and Headwinds to Outlook:

• Enrollment Risk: High diagnostic complexity of MSA may slow recruitment speed compared to less selective trials.
• Trial Failure: Inherent uncertainty regarding the magnitude of the treatment effect in a larger sample size despite robust Phase 2 signals; variability in patient response remains a risk.
• Financial Risk: Dependence on external capital or partnership to fund the trial post-initial cash runway; potential dilution from future equity raises.
• Operational Risk: Complexity of recruiting patients with specific MRI and biomarker profiles (elevated NFL, specific brain atrophy) across multinational sites.

Management Tone on the Future:

• Confidence Level: High confidence in Phase 3 success due to the breadth of efficacy across clinical, patient-reported, and objective endpoints, and the safety profile demonstrated in Phase 2.
• Guidance Stability: No changes to prior guidance mentioned; tone suggests a "de-risked" and "refined" approach to Phase 3 rather than a pivot.
• Certainty: Management explicitly states they "don't see any major uncertainties" regarding the proceeding, viewing the Phase 3 as a confirmation of Phase 2 findings rather than a discovery phase.

Miscellaneous:

• Dose Rationale: The 50 mg dose was chosen over 75 mg because the 75 mg group in Phase 2 exhibited higher baseline disease severity (rapid progression markers), which skewed the apparent efficacy, whereas 50 mg demonstrated a saturated exposure-response curve.
• Biomarker Evolution: Shift from using only MRI iron signatures in Phase 2 to a combination of brain volume (MRI) and plasma NFL, with spinal fluid NFL also included in the Phase 3 analysis plan.